Form 13-F position report

LIGAND PHARMACEUTICALS INC

Reported by ASHFORD CAPITAL MANAGEMENT INC

LGND CUSIP 53220K504 Manager CIK 0000897070

Reported 166,336 shares, down 3,900 (2.3%) from the prior quarter.

Reported value -3.4%; share count -2.3% vs. the prior quarter.

Reduced
% of reported 13F value 5.62% This manager · Q3 2026
Shares 166,336 Quarter-end amount reported
Reported value $51,958,376 Fair value at quarter end
Consecutive quarters held 11 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 470000
2022-03-31 0
2024-03-31 14366709
2024-06-30 27149162
2024-09-30 31068637
2024-12-31 33287648
2025-03-31 31335400
2025-06-30 34391269
2025-09-30 43298330
2025-12-31 40419006
2026-03-31 41440352
2026-06-30 53809897
2026-09-30 51958376

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for LIGAND PHARMACEUTICALS INC held by ASHFORD CAPITAL MANAGEMENT INC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 166,336 -3,900 (-2.3%) 5.62% $51,958,376 2026-11-13
Q2 2026 Reduced 170,236 -37,329 (-18.0%) 5.77% $53,809,897 2026-08-21
Q1 2026 Reduced 207,565 -6,213 (-2.9%) 5.12% $41,440,352 2026-05-15
Q4 2025 Reduced 213,778 -30,652 (-12.5%) 4.5% $40,419,006 2026-02-17
Q3 2025 Reduced 244,430 -58,097 (-19.2%) 4.82% $43,298,330 2025-11-14
Q2 2025 Added 302,527 +4,492 (1.5%) 4.04% $34,391,269 2025-08-18
Q1 2025 Reduced 298,035 -12,629 (-4.1%) 4.04% $31,335,400 2025-05-15
Q4 2024 Added 310,664 +257 (0.1%) 3.93% $33,287,648 2025-02-18
Q3 2024 Reduced 310,407 -11,800 (-3.7%) 3.88% $31,068,637 2024-11-18
Q2 2024 Added 322,207 +125,672 (63.9%) 3.67% $27,149,162 2024-08-15
Q1 2024 New 196,535 +196,535 (0.0%) 1.94% $14,366,709 2024-05-15
Q1 2022 Reduced 0 -3,040 (-100.0%) 0 $0 2022-05-16
Q4 2021 Unchanged 3,040 0 (0.0%) 0.05% $470,000 2022-02-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

476 managers reported LIGAND PHARMACEUTICALS INC for Q3 2026.

Managers reporting LIGAND PHARMACEUTICALS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 3,112,206 +11,210 0.01% $972,159,789 9 qtrs
Invesco Ltd Added 1,503,709 +302,065 0.04% $469,713,581 54 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 1,112,046 -26,270 0.02% $347,369,809 3 qtrs
FRANKLIN RESOURCES INC Added 912,311 +160,267 0.06% $288,408,877 14 qtrs
JANUS HENDERSON GROUP PLC Reduced 914,350 -95,541 0.12% $285,618,711 1 qtr
VANGUARD CAPITAL MANAGEMENT LLC Reduced 869,478 -1,472 < 0.01% $271,598,843 3 qtrs
STATE STREET CORPORATION Added 834,685 +8,146 < 0.01% $260,730,553 54 qtrs
FMR LLC Reduced 698,920 -63,907 < 0.01% $218,321,723 54 qtrs
CONGRESS ASSET MANAGEMENT CO MA Reduced 658,556 -1,355 1.33% $205,713,138 10 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 586,811 -2,209 < 0.01% $183,332,090 54 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
166,336
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.